Liquid biopsy for profiling of cfDNA is transforming researchers’ efforts in early cancer detection, risk stratification, and disease monitoring. This poster illustrates how capturing complete genetic and modified cytosine (modC) information in one workflow, from a single low-volume DNA sample is morepowerful for the detection of early cancer than either alone.
- Preserving Valuable Samples: Generate high-quality genomic and epigenomic data from a low-input sample, even 10 ng of cfDNA.
- Suppressing Errors: Obtain more sensitive somatic variant calling through error suppression.
- Achieving Multiomics Data & Analysis: Get multi-modal information from cfDNA while avoiding bisulfite damage and data loss.